

## **Michigan Quality Improvement Consortium Guideline**

## Primary Care Diagnosis and Management of Adults with Depression

The following guideline recommends screening for depression, assessing suicide risk, following diagnostic criteria, shared decision-making and treatment planning, monity				nitoring and adjusting treatment.	
<b>Eligible Population</b>	Recommendation and Level of Evidence			Frequency	
Adults 18 years or older, including pregnant and	Detection and Diagnosis:  Screen for depression, using a validated screening tool (e.g. PHQ-2 or 9, Edinburgh Scale) with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up. [B]  Assess for other causes of symptoms, and comorbid conditions that might impact treatment (e.g., medical and medication-induced conditions, drug or alcohol abuse, bipolar disorder, anxiety disorders, psychosis).			Annually. More often if high risk.	
postpartum women				Pregnant and postpartum women At the first prenatal care visit; on post-partum visits (within 3-8	
	Assess the clinical, social and socioeconomic risk factors that may be uniquely associated with perinatal depression.  Assess if criteria are met using DSM-5 criteria. [A] Criteria A, B, C and D must be met.				
	DSM-5 criteria	Major Depression	Persistent Depressive Disorder	<ul><li>weeks of discharge) and if</li><li>symptoms or signs raise</li><li>suspicion using the</li></ul>	
		5 total for ≥ 2 weeks and	3 total for ≥ 2 years.		
	A. Symptoms	must include symptom #1 or #2	Must include symptom #1. Never > 2 months symptom-free	Edinburgh Postnatal	
	1. Depressed mood	X	X	Depression Scale <sup>1</sup> .	
	2. Marked diminished interest/pleasure	х		1	
	3. Significant weight gain/loss, appetite decrease/increase	х	X	1	
	4. Insomnia/hypersomnia	x	Х	1	
	5. Psychomotor agitation/retardation noticeable by others	X		7	
	6. Fatigue/loss of energy	Х	X		
	7. Feelings of worthlessness or inappropriate guilt	Х	X		
	Diminished concentration or indecisiveness	Х	X		
	Recurrent thoughts of death or suicidal ideation	X			
	10. Hopelessness		X		
	B. Symptoms cause clinically significant distress or impairment in functioning			_	
	C. Symptoms not attributed to a substance or other medical condition  D. Lack of psychotic disorder or history of manic or hypomanic symptoms			4	
Individuals diagnosed	attempts. [D] See established clinical tools for risk assessment and suicide prevention <sup>2,3</sup> . If applicable, develop safety plan. ■ If patient at moderate to severe risk for suicide, transfer to emergency department or crisis intervention center.			At each encounter addressing	
with a depressive disorder				depression until patient is treated to remission.	
				Schedule sufficient follow-up visits	
				to assess response to treatment	
	stress-management, social support, spiritual support, online resources). <b>[C]</b> Utilize shared decision-making in treatment planning. <b>[A]</b> Consider onset and severity of symptoms, impairment, past episodes, psychosocial stressors, medical and psychiatric comorbidities, patient preference, resource accessibility. For mild to moderate symptoms consider pharmacotherapy and/or			and titrate dose (typically every two	
				weeks, monthly at a minimum). <b>[D]</b>	
	evidence-based psychotherapy. <b>[A]</b> For severe symptoms consider both pharmacotherapy and evidence-based psychotherapy. <b>[A]</b> Monitor response to treatment using standardized scale (e.g., PHQ-9) at least every 4 months until remission is obtained. On PHQ-9, adequate response				
	is 50% reduction in score, remission=total score <5.				
	Consider referral to behavioral health specialist when additional counseling is desired, primary physician is not comfortable managing patient's depression,				
	diagnostic uncertainty, complex symptoms or social situation, pregnancy, response to medication at therapeutic dose is not optimal, considering				
	prescribing multiple agents, or more extensive interventions are warranted. [D]				
	If initiating antidepressant medication, follow manufacturer's recommended doses. Avoid underdosing. If inadequate response after 2-4 weeks, increase dosage as tolerated not to exceed the highest recommended dose unless directed by a psychiatrist. If discontinuing antidepressant, be aware of need to				
	taper some medications.				
	If limited or no response to treatment, assess for non-adherence, inadequate dosing, diagnostic inaccuracy or comorbid conditions exacerbating symptoms.				
	Consider: increased doses of medication or frequency of psychotherapy, switching treatments or augment treatment with other medications or				
	psychotherapeutic interventions, consultation.				
	Monitoring: If medication prescribed, continue treatment and monitoring for at least 9-12 months after acute symptoms resolve. [A] Patients with recurrent				
1	major depression and/or persistent depressive disorder (≥ 2 years) usually require lifelong treatment.			<u>l</u>	
<sup>1</sup> Edinburgh Postnatal Depressio <sup>2</sup> Suicide Prevention for Primary					

Suicide Prevention for Primary Care Toolkit

Levels of Evidence for the most significant recommendations: A = randomized controlled trials; B = controlled trials, no randomization; C = observational studies; D = opinion of expert panel

This guideline is based on several sources, including: Final Update Summary: Depression in Adults: Screening. U.S. Preventive Services Task Force, January 2016; Final Recommendation Statement: Perinatal Depression: Preventive Interventions: U.S. Preventive Services Task Force, February 2019; American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders Fifth Edition - DSM-5; Nonpharmacological Versus Pharmacological Versus Pharmac

<sup>&</sup>lt;sup>3</sup>Suicide Assessment Five-step Evaluation and Triage